Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Total Non-Current Liabilities (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Total Non-Current Liabilities for 8 consecutive years, with $120.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities fell 2.85% year-over-year to $120.5 million, compared with a TTM value of $120.5 million through Dec 2025, down 2.85%, and an annual FY2025 reading of $120.5 million, down 2.85% over the prior year.
  • Total Non-Current Liabilities was $120.5 million for Q4 2025 at Zevra Therapeutics, down from $133.0 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $133.0 million in Q3 2025 and bottomed at $5.4 million in Q3 2021.
  • Average Total Non-Current Liabilities over 5 years is $66.4 million, with a median of $59.1 million recorded in 2023.
  • The sharpest move saw Total Non-Current Liabilities plummeted 92.62% in 2021, then surged 675.95% in 2022.
  • Year by year, Total Non-Current Liabilities stood at $5.8 million in 2021, then soared by 593.97% to $40.2 million in 2022, then soared by 156.26% to $103.0 million in 2023, then grew by 20.41% to $124.0 million in 2024, then fell by 2.85% to $120.5 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for ZVRA at $120.5 million in Q4 2025, $133.0 million in Q3 2025, and $121.6 million in Q2 2025.